Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus PULMICORT FLEXHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus PULMICORT FLEXHALER.
ARNUITY ELLIPTA vs PULMICORT FLEXHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid